Biologics Manufacturing Service
Hisun’s Biologics division has been in operation since 2003. Operating over the two manufacturing sites, our areas of expertise include monoclonal antibody, Recombinant protein and Fusion protein/peptide/cell factor/vaccine, antibody drug conjugation. Hisun was the first to develop and launch a bio-better version of Enbrel, in China, and we currently have several bio-similar products in late stage clinical development. Our highly skilled biologics team welcomes the opportunity to provide custom services and co-development of biosimilars for different countries. We apply our breadth of technologies, skilled workforce, and state-of-the-art facilities while leveraging a cost competitive base for the benefit or our clients and partners.
Biologics Manufacturing Capability
Monoclonal Antibody
- Recombinant and Fusion Protein
- Peptide
- Cell Factor
- Vaccine
- Antibody Drug Conjugates
Protein Engineering
- Cell Line development
- Cloning
- Protein expression
Biologics Manufacturing Capacity
- Cell culture lines -- up to 2x300L, 2x2, 250L
- Microbial lines -- 500L, 2x15,00L